{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:25:05Z","timestamp":1789176305289,"version":"build-2803163510"},"reference-count":92,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014593","name":"Neurocrine Biosciences, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Crinecerfont, a first-in-class corticotropin-releasing factor type 1 receptor antagonist, is FDA-approved as an adjunct to the physiologic glucocorticoid (GC) required to treat the underlying adrenal insufficiency in patients (\u22654 years old) with classic congenital adrenal hyperplasia (CAH). By reducing elevated adrenocorticotropic hormone, crinecerfont controls excess adrenal androgens, thereby enabling lower GC doses. However, there are no published recommendations for how to reduce supraphysiologic GC doses after initiating crinecerfont. This manuscript aims to provide a framework developed by experienced endocrinologists for reducing supraphysiologic GC doses in patients taking crinecerfont.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence Acquisition<\/jats:title>\n                    <jats:p>An experienced panel of 11 endocrinologists discussed strategies and considerations when reducing GC doses and developed an algorithm to guide GC dose reductions after introducing crinecerfont in adults with CAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence Synthesis<\/jats:title>\n                    <jats:p>Approaches to GC reduction should be individualized based on the patient's therapeutic goals, cortisol needs, lifestyle preferences, and the clinician's experience to set appropriate targets for clinical parameters, androgens, and GC dose regimen. In general, GC doses should be reduced gradually to minimize the risks of developing symptoms of GC withdrawal or adrenal insufficiency. GC doses should be adjusted to the lowest level needed to maintain androgens at goal, without reducing below what is needed for cortisol replacement. Practical considerations during GC dose reduction include switching from longer- to shorter-acting GCs (eg, from dexamethasone to hydrocortisone), optimizing dose distribution to mimic normal circadian cortisol exposure, and consolidating or eliminating doses to improve adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This framework for reducing supraphysiologic GC doses in adult patients taking crinecerfont may become increasingly relevant as treatment of CAH shifts toward physiologic GC replacement with adjunctive control of adrenal androgens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag147","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:42:41Z","timestamp":1775043761000},"page":"1801-1812","source":"Crossref","is-referenced-by-count":1,"title":["Glucocorticoid reduction after starting crinecerfont in adult patients with classic CAH: practical perspectives"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7367-3885","authenticated-orcid":false,"given":"Oksana","family":"Hamidi","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX 75390 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Auchus","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Endocrinology, and Diabetes, Departments of Internal Medicine and Pharmacology, University of Michigan Medical School , Ann Arbor, MI 48109 , USA"},{"name":"Endocrinology and Metabolism Section, Medicine Service, LTC Charles S. Kettles Veterans Affairs Medical Center , Ann Arbor, MI 48105 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Correa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Medical Specialty Institute, Cleveland Clinic , Cleveland, OH 44195 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0634-4133","authenticated-orcid":false,"given":"Alice C","family":"Levine","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, NY 10029 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7634-1093","authenticated-orcid":false,"given":"Margaret E","family":"Wierman","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Integrative Physiology, and OBGYN, University of Colorado Anschutz Medical Campus , Aurora, CO 80045 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L","family":"Hartzell","sequence":"additional","affiliation":[{"name":"Medical Affairs, Neurocrine Biosciences , San Diego, CA 92130 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian H","family":"Lin","sequence":"additional","affiliation":[{"name":"Medical Affairs, Neurocrine Biosciences , San Diego, CA 92130 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9332-2524","authenticated-orcid":false,"given":"Irina","family":"Bancos","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo Clinic , Rochester, MN 55905 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"13","key":"2026061619574907500_dgag147-B1","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMra1909786","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"383","author":"Merke","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"2026061619574907500_dgag147-B2","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"10372","key":"2026061619574907500_dgag147-B3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(22)01330-7","article-title":"Congenital adrenal hyperplasia","volume":"401","author":"Auer","year":"2023","journal-title":"Lancet"},{"issue":"Suppl 1","key":"2026061619574907500_dgag147-B4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1210\/clinem\/dgae535","article-title":"Genetics and pathophysiology of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"110","author":"Yang","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"10108","key":"2026061619574907500_dgag147-B5","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/S0140-6736(17)31431-9","article-title":"Congenital adrenal hyperplasia","volume":"390","author":"El-Maouche","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"2026061619574907500_dgag147-B6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41574-022-00655-w","article-title":"Management challenges and therapeutic advances in congenital adrenal hyperplasia","volume":"18","author":"Mallappa","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2026061619574907500_dgag147-B7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/endrev\/bnab016","article-title":"Congenital adrenal hyperplasia\u2013current insights in pathophysiology, diagnostics, and management","volume":"43","author":"Claahsen-van der Grinten","year":"2022","journal-title":"Endocr Rev"},{"issue":"9","key":"2026061619574907500_dgag147-B8","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1210\/clinem\/dgad134","article-title":"Interpretation of steroid biomarkers in 21-hydroxylase deficiency and their use in disease management","volume":"108","author":"Sarafoglou","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"10274","key":"2026061619574907500_dgag147-B9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(21)00136-7","article-title":"Adrenal insufficiency","volume":"397","author":"Husebye","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2026061619574907500_dgag147-B10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/17446651.2025.2450423","article-title":"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms","volume":"20","author":"Bancos","year":"2025","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"12","key":"2026061619574907500_dgag147-B11","doi-asserted-by":"crossref","first-page":"E2715","DOI":"10.1210\/jc.2014-2957","article-title":"Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"99","author":"Falhammar","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026061619574907500_dgag147-B12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/ejendo\/lvae023","article-title":"Frequency of stress dosing and adrenal crisis in paediatric and adult patients with congenital adrenal hyperplasia: a prospective study","volume":"190","author":"Tschaidse","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026061619574907500_dgag147-B13","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1210\/jc.2018-00208","article-title":"Longitudinal assessment of illnesses, stress dosing, and illness sequelae in patients with congenital adrenal hyperplasia","volume":"103","author":"El-Maouche","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026061619574907500_dgag147-B14","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMra1807486","article-title":"Adrenal crisis","volume":"381","author":"Rushworth","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"2026061619574907500_dgag147-B15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000489385","article-title":"Clitoromegaly in childhood and adolescence: behind one clinical sign, a clinical sea","volume":"12","author":"Iezzi","year":"2018","journal-title":"Sex Dev"},{"issue":"6","key":"2026061619574907500_dgag147-B16","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jpurol.2013.03.013","article-title":"Current practice in feminizing surgery for congenital adrenal hyperplasia; a specialist survey","volume":"9","author":"Yankovic","year":"2013","journal-title":"J Pediatr Urol"},{"issue":"Suppl 1","key":"2026061619574907500_dgag147-B17","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1210\/clinem\/dgae563","article-title":"Clinical manifestations and treatment challenges in infants and children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"110","author":"Nokoff","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026061619574907500_dgag147-B18","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1515\/jpem-2016-0156","article-title":"Growth curves for congenital adrenal hyperplasia from a national retrospective cohort","volume":"29","author":"Bretones","year":"2016","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"9","key":"2026061619574907500_dgag147-B19","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1210\/jc.2009-2616","article-title":"Clinical review: adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis","volume":"95","author":"Muthusamy","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026061619574907500_dgag147-B20","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1210\/clinem\/dgaa801","article-title":"Reproductive and perinatal outcomes in women with congenital adrenal hyperplasia: a population-based cohort study","volume":"106","author":"Hirschberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026061619574907500_dgag147-B21","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1210\/en.2019-00101","article-title":"Physiological and pathological androgen actions in the ovary","volume":"160","author":"Astapova","year":"2019","journal-title":"Endocrinology"},{"issue":"6","key":"2026061619574907500_dgag147-B22","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1210\/endrev\/bnad016","article-title":"Treating the side effects of exogenous glucocorticoids; can we separate the good from the bad?","volume":"44","author":"Pofi","year":"2023","journal-title":"Endocr Rev"},{"issue":"Suppl 1","key":"2026061619574907500_dgag147-B23","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1210\/clinem\/dgae696","article-title":"Clinical manifestations and challenges in adolescent and adult females with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"110","author":"Engberg","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026061619574907500_dgag147-B24","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1530\/EJE-20-1093","article-title":"Management of endocrine disease: gonadal dysfunction in congenital adrenal hyperplasia","volume":"184","author":"Claahsen-van der Grinten","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"2026061619574907500_dgag147-B25","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1210\/clinem\/dgae718","article-title":"Challenges in adolescent and adult males with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"110","author":"Claahsen-van der Grinten","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026061619574907500_dgag147-B26","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1210\/er.2018-00258","article-title":"Testicular adrenal rest tumors: current insights on prevalence, characteristics, origin, and treatment","volume":"40","author":"Engels","year":"2019","journal-title":"Endocr Rev"},{"issue":"1","key":"2026061619574907500_dgag147-B27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jpurol.2023.10.005","article-title":"Testicular adrenal rest tumors\u2014epidemiology, diagnosis and treatment","volume":"20","author":"Eyer de Jesus","year":"2024","journal-title":"J Pediatr Urol"},{"issue":"4","key":"2026061619574907500_dgag147-B28","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/cen.14967","article-title":"Long-term health consequences of congenital adrenal hyperplasia","volume":"101","author":"Pofi","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2026061619574907500_dgag147-B29","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1365-2265.2009.03563.x","article-title":"Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate","volume":"70","author":"Caster\u00e0s","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026061619574907500_dgag147-B30","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.fertnstert.2007.03.051","article-title":"Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia can cause severe testicular damage","volume":"89","author":"Claahsen-van der Grinten","year":"2008","journal-title":"Fertil Steril"},{"issue":"6","key":"2026061619574907500_dgag147-B31","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/cen.13001","article-title":"Experience in optimizing fertility outcomes in men with congenital adrenal hyperplasia due to 21 hydroxylase deficiency","volume":"84","author":"King","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026061619574907500_dgag147-B32","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.fertnstert.2017.08.013","article-title":"Fertility outcome and information on fertility issues in individuals with different forms of disorders of sex development: findings from the dsd-LIFE study","volume":"108","author":"Slowikowska-Hilczer","year":"2017","journal-title":"Fertil Steril"},{"key":"2026061619574907500_dgag147-B33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fendo.2019.00212","article-title":"Cardiovascular health in children and adolescents with congenital adrenal hyperplasia due to 21-hydroxilase deficiency","volume":"10","author":"Improda","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2026061619574907500_dgag147-B34","first-page":"e5247","article-title":"Cardiovascular disease risk factors and metabolic morbidity in a longitudinal study of congenital adrenal hyperplasia","volume":"106","author":"Torky","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026061619574907500_dgag147-B35","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/archdischild-2016-311910","article-title":"Cardiovascular health, growth and gonadal function in children and adolescents with congenital adrenal hyperplasia","volume":"102","author":"Mooij","year":"2017","journal-title":"Arch Dis Child"},{"issue":"1","key":"2026061619574907500_dgag147-B36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/endrev\/bnae026","article-title":"Cardiometabolic aspects of congenital adrenal hyperplasia","volume":"46","author":"Krysiak","year":"2025","journal-title":"Endocr Rev"},{"issue":"11","key":"2026061619574907500_dgag147-B37","doi-asserted-by":"crossref","first-page":"bvaa145","DOI":"10.1210\/jendso\/bvaa145","article-title":"Empiric determination of the daily glucocorticoid replacement dose in adrenal insufficiency","volume":"4","author":"Caetano","year":"2020","journal-title":"J Endocr Soc"},{"issue":"1","key":"2026061619574907500_dgag147-B38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/jc.2003-030440","article-title":"Association of 24-hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women","volume":"89","author":"Purnell","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061619574907500_dgag147-B39","doi-asserted-by":"crossref","first-page":"2042018818821294","DOI":"10.1177\/2042018818821294","article-title":"Novel insights into glucocorticoid replacement therapy for pediatric and adult adrenal insufficiency","volume":"10","author":"Oprea","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2026061619574907500_dgag147-B40","doi-asserted-by":"crossref","first-page":"897211","DOI":"10.3389\/fendo.2022.897211","article-title":"Daily glucocorticoid replacement dose in adrenal insufficiency, a mini review","volume":"13","author":"Caetano","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026061619574907500_dgag147-B41","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026061619574907500_dgag147-B42","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1210\/jc.2010-0917","article-title":"Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients","volume":"95","author":"Arlt","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026061619574907500_dgag147-B43","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1530\/EJE-10-0877","article-title":"Cardiovascular risk, metabolic profile, and body composition in adult males with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"164","author":"Falhammar","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2026061619574907500_dgag147-B44","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1210\/JC.2015-2093","article-title":"Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: a Swedish population-based national cohort study","volume":"100","author":"Falhammar","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026061619574907500_dgag147-B45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3803\/EnM.2021.1328","article-title":"Epidemiology and long-term adverse outcomes in Korean patients with congenital adrenal hyperplasia: a nationwide study","volume":"37","author":"Kim","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"1","key":"2026061619574907500_dgag147-B46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12020-021-02723-z","article-title":"Rate of fracture in patients with glucocorticoid replacement therapy: a systematic review and meta-analysis","volume":"74","author":"Li","year":"2021","journal-title":"Endocrine"},{"key":"2026061619574907500_dgag147-B47","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3389\/fendo.2020.00493","article-title":"Bone mineral density in adults with congenital adrenal hyperplasia: a systematic review and meta-analysis","volume":"11","author":"Rangaswamaiah","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026061619574907500_dgag147-B48","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1210\/clinem\/dgab712","article-title":"Increased prevalence of fractures in congenital adrenal hyperplasia: a Swedish population-based national cohort study","volume":"107","author":"Falhammar","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026061619574907500_dgag147-B49","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"2026061619574907500_dgag147-B50","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2265.1996.8620871.x","article-title":"Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency","volume":"45","author":"Jaaskelainen","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2026061619574907500_dgag147-B51","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-15-1096","article-title":"Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency","volume":"174","author":"Schulz","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026061619574907500_dgag147-B52","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1530\/eje.0.1430667","article-title":"Bone mass and body composition of adult women with congenital virilizing 21-hydroxylase deficiency after glucocorticoid treatment since infancy","volume":"143","author":"Hagenfeldt","year":"2000","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026061619574907500_dgag147-B53","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2265.2008.03518.x","article-title":"Bone mineral density and bone turnover in Romanian children and young adults with classical 21-hydroxylase deficiency are influenced by glucocorticoid replacement therapy","volume":"71","author":"Zimmermann","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2026061619574907500_dgag147-B54","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1210\/jc.2006-0524","article-title":"The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients","volume":"91","author":"Filipsson","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026061619574907500_dgag147-B55","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1210\/jc.2007-0744","article-title":"Fractures and bone mineral density in adult women with 21-hydroxylase deficiency","volume":"92","author":"Falhammar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026061619574907500_dgag147-B56","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-12-0865","article-title":"Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia","volume":"168","author":"Falhammar","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"2026061619574907500_dgag147-B57","author":"Sharma"},{"issue":"2","key":"2026061619574907500_dgag147-B58","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/cen.12045","article-title":"Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia","volume":"78","author":"Han","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2026061619574907500_dgag147-B59","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000333696","article-title":"Adrenarche and puberty in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"76","author":"Volkl","year":"2011","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"2026061619574907500_dgag147-B60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.15605\/jafes.037.AFES.13","article-title":"Association between glucocorticoid dose with BMI and glucocorticoid-related comorbidities: data from tildacerfont phase 2a trials in classic congenital adrenal hyperplasia","volume":"37","author":"Kim","year":"2022","journal-title":"J ASEAN Fed Endocr Soc"},{"issue":"7","key":"2026061619574907500_dgag147-B61","doi-asserted-by":"crossref","first-page":"e14233","DOI":"10.1111\/ijcp.14233","article-title":"Cardiovascular dysfunction risk in young adults with congenital adrenal hyperplasia caused by 21-hydroxylase enzyme deficiency","volume":"75","author":"Borges","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"11","key":"2026061619574907500_dgag147-B62","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1210\/jc.2018-01862","article-title":"Cardiovascular and metabolic outcomes in congenital adrenal hyperplasia: a systematic review and meta-analysis","volume":"103","author":"Tamhane","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061619574907500_dgag147-B63","doi-asserted-by":"crossref","first-page":"105540","DOI":"10.1016\/j.jsbmb.2019.105540","article-title":"Effect of androgen excess and glucocorticoid exposure on metabolic risk profiles in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"197","author":"Paizoni","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"2026061619574907500_dgag147-B64","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1210\/js.2019-00136","article-title":"Glucocorticoid regimens in the treatment of congenital adrenal hyperplasia: a systematic review and meta-analysis","volume":"3","author":"Whittle","year":"2019","journal-title":"J Endocr Soc"},{"issue":"5","key":"2026061619574907500_dgag147-B65","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1210\/jc.2013-4253","article-title":"Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of Addison's disease: a randomized clinical trial","volume":"99","author":"Oksnes","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026061619574907500_dgag147-B66","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/cen.13813","article-title":"Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia","volume":"89","author":"Mallappa","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026061619574907500_dgag147-B67","doi-asserted-by":"crossref","first-page":"5315059","DOI":"10.1155\/2023\/5315059","article-title":"Patients with hypocortisolism treated with continuous subcutaneous hydrocortisone infusion (CSHI): an option for poorly controlled patients","volume":"2023","author":"Mortensen","year":"2023","journal-title":"Int J Endocrinol"},{"issue":"3","key":"2026061619574907500_dgag147-B68","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S2213-8587(17)30398-4","article-title":"Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial","volume":"6","author":"Isidori","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2026061619574907500_dgag147-B69","doi-asserted-by":"crossref","first-page":"e2063","DOI":"10.1210\/clinem\/dgab051","article-title":"Modified-release hydrocortisone in congenital adrenal hyperplasia","volume":"106","author":"Merke","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2026061619574907500_dgag147-B70","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1210\/clinem\/dgae759","article-title":"Future directions in the management of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"110","author":"Sarafoglou","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2026061619574907500_dgag147-B71","first-page":"OR25","article-title":"The effects of crinecerfont (NBI-74788), a novel CRF1 receptor antagonist, on adrenal androgens and precursors in patients with classic congenital adrenal hyperplasia: results from a multiple-dose phase 2 study","volume":"4","author":"Auchus","year":"2020","journal-title":"J Endocr Soc"},{"issue":"11","key":"2026061619574907500_dgag147-B72","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1210\/clinem\/dgad270","article-title":"Crinecerfont, a CRF1 receptor antagonist, lowers adrenal androgens in adolescents with congenital adrenal hyperplasia","volume":"108","author":"Newfield","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026061619574907500_dgag147-B73","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2404656","article-title":"Phase 3 trial of crinecerfont in adult congenital adrenal hyperplasia","volume":"391","author":"Auchus","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061619574907500_dgag147-B74","volume-title":"Crinecerfont maintains adrenocorticotropic hormone and 17-hydroxyprogesterone levels with reduced glucocorticoid doses in adults with classic congenital adrenal hyperplasia: 1-year results from the","author":"Auchus"},{"issue":"6","key":"2026061619574907500_dgag147-B75","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2404655","article-title":"Phase 3 trial of crinecerfont in pediatric congenital adrenal hyperplasia","volume":"391","author":"Sarafoglou","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061619574907500_dgag147-B76","author":"Geffner"},{"issue":"Suppl 1","key":"2026061619574907500_dgag147-B77","first-page":"A152","article-title":"Safety and pharmacokinetics of anti-ACTH antibody Lu AG13909 in patients with classic congenital adrenal hyperplasia: phase 1 open-label, multiple-ascending-dose trial protocol","volume":"5","author":"Srirangalingam","year":"2024","journal-title":"J Endocr Soc"},{"issue":"Suppl 1","key":"2026061619574907500_dgag147-B78","first-page":"A134","article-title":"Once daily oral atumelnant (CRN04894) induces rapid and profound reductions of androstenedione and 17-hydroxyprogesterone in participants with classical congenital adrenal hyperplasia: initial results from a 12-week, phase 2, open-label study","volume":"8","author":"Auchus","year":"2024","journal-title":"J Endocr Soc"},{"issue":"8","key":"2026061619574907500_dgag147-B79","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1210\/clinem\/dgaa381","article-title":"A phase 2, multicenter study of nevanimibe for the treatment of congenital adrenal hyperplasia","volume":"105","author":"El-Maouche","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061619574907500_dgag147-B80","volume-title":"CRENESSITY\u00ae(Crinecerfont) Capsules and CRENESSITY\u00ae (Crinecerfont) Oral Solution Full Prescribing Information","author":"Neurocrine Biosciences, Inc","year":"2024"},{"issue":"5","key":"2026061619574907500_dgag147-B81","first-page":"G25","article-title":"European Society of Endocrinology and Endocrine Society joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency","volume":"190","author":"Beuschlein","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026061619574907500_dgag147-B82","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1373\/clinchem.2010.146035","article-title":"Monitoring of therapy in congenital adrenal hyperplasia","volume":"56","author":"Dauber","year":"2010","journal-title":"Clin Chem"},{"issue":"1","key":"2026061619574907500_dgag147-B83","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/jcem-33-1-14","article-title":"Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects","volume":"33","author":"Weitzman","year":"1971","journal-title":"J Clin Endocrinol Metab"},{"issue":"26","key":"2026061619574907500_dgag147-B84","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1016\/S0024-3205(97)01008-4","article-title":"Free cortisol levels after awakening: a reliable biological marker for the assessment of adrenocortical activity","volume":"61","author":"Pruessner","year":"1997","journal-title":"Life Sci"},{"issue":"4","key":"2026061619574907500_dgag147-B85","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1542\/peds.106.4.767","article-title":"Dexamethasone treatment of virilizing congenital adrenal hyperplasia: the ability to achieve normal growth","volume":"106","author":"Rivkees","year":"2000","journal-title":"Pediatrics"},{"key":"2026061619574907500_dgag147-B86","volume-title":"The Diagnosis and Treatment of Endocrine Disorders in Childhood and Adolescence","author":"Wilkins","year":"1950","edition":"1st ed"},{"issue":"6):","key":"2026061619574907500_dgag147-B87","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1159\/000374112","article-title":"Influence of 17-hydroxyprogesterone, progesterone and sex steroids on mineralocorticoid receptor transactivation in congenital adrenal hyperplasia","volume":"83","author":"Mooij","year":"2015","journal-title":"Horm Res Paediatr"},{"issue":"4","key":"2026061619574907500_dgag147-B88","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/cen.14959","article-title":"Mineralocorticoid replacement therapy in salt-wasting congenital adrenal hyperplasia","volume":"101","author":"Lang","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2026061619574907500_dgag147-B89","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000327794","article-title":"Health problems in congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"76","author":"Reisch","year":"2011","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"2026061619574907500_dgag147-B90","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/ajh\/hpv087","article-title":"Blood pressure in a large cohort of children and adolescents with classic adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency","volume":"29","author":"Bonfig","year":"2016","journal-title":"Am J Hypertens"},{"issue":"Suppl 1","key":"2026061619574907500_dgag147-B91","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1210\/clinem\/dgae728","article-title":"Life with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: challenges and burdens","volume":"110","author":"Witchel","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026061619574907500_dgag147-B92","doi-asserted-by":"crossref","first-page":"258","DOI":"10.7861\/clinmedicine.17-3-258","article-title":"Adrenal insufficiency\u2014recognition and management","volume":"17","author":"Pazderska","year":"2017","journal-title":"Clin Med (Lond)"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag147\/67719551\/dgag147.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/1801\/67719551\/dgag147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/1801\/67719551\/dgag147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:58:04Z","timestamp":1781654284000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/7\/1801\/8571825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":92,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4,1]]},"published-print":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag147","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,1]]}}}